An American company has claimed a new four-in-one treatment for HIV can reduce patients’ viral load.
Biopharmaceutical company, Gilead Sciences Inc, is currently testing the single-tablet treatment, which consists of elvitegravir, cobicistat and Truvada.
The drug, which includes emtricitabine and tenofovir disoproxil fumarate, successfully reduced the viral load in patients during a midstage study.
Gilead already produces three-in-one HIV treatment Atripla. The new findings were presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston on Monday 13 September.
Copyright Press Association 2010